Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh
Hemachandra
H
US Oncology Research, Inc., Houston, TX 77090, USA.
Di Bella
Nicholas
N
Flynn
Thomas P
TP
Vellek
Mark J
MJ
Boehm
Kristi A
KA
Asmar
Lina
L
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine